Omeros Corporation Stock News

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

Hidden gems often remain undiscovered within the labyrinth of the stock market. Three stocks with massive upside stand out among the several alternatives as possible titans with significant upside pot

In general, high-growth stocks  and sleeper stocks under $15 are associated with valuation concerns. Let's forget inflated giants and overhyped darlings.

While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it's time to address this speculative p

Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and

Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023, on Wednesday, August 9, 2023, before

Omeros Corporation's share price has seen significant run-ups in recent months despite disappointing first quarter results in 2023 and the company's lack of profitability. The company was awarded $6.6

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, Ju

The company's lead therapy, Narsoplimab, has not yet been approved. As of the first quarter, Omeros had $371.4 million in cash.

Omeros Corporation (NASDAQ:OMER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and CEO Mike Jacobsen - C

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 202

Omeros Corporation (NASDAQ:OMER ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Dr. Greg Demopulos - Chairman and CEO Mike Jaco

A $200 million milestone payment sparked a rally in the biopharma's shares this week.

Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang some investors were worried about. With the additiona